肠溶包衣萘普生治疗骨关节炎和类风湿关节炎的开放标签耐受性研究。
Open-label tolerability study of enteric-coated naproxen in the treatment of osteoarthritis and rheumatoid arthritis.
作者信息
Bellamy N, Beaulieu A, Bombardier C, Esdaile J, Huang S, Jovaisas A V, Khanna V N, Kraag G, Mehta D M, Ménard H A
机构信息
Department of Medicine, University of Western Ontario, London, Canada.
出版信息
Curr Med Res Opin. 1992;12(10):652-61. doi: 10.1185/03007999209111532.
Two hundred and ninety-six patients were enrolled in a 6-month, open-label tolerability study of enteric-coated naproxen in patients with rheumatoid arthritis (n = 174) and osteoarthritis (n = 122). Thirty percent of the patients were greater than 65 years of age. Under standard clinical prescribing conditions, enteric-coated naproxen 500 mg twice daily and 375 mg twice daily demonstrated an acceptable tolerability profile that was not different from what one would expect with standard naproxen.
296名患者参与了一项为期6个月的肠溶萘普生开放性耐受性研究，这些患者患有类风湿性关节炎（n = 174）和骨关节炎（n = 122）。30%的患者年龄超过65岁。在标准临床处方条件下，每日两次服用500毫克和每日两次服用375毫克的肠溶萘普生显示出可接受的耐受性，与标准萘普生的预期耐受性无异。
Zotero 插件